Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults

G. Krumpl, I. Ulč, M. Trebs, P. Kadlecová, J. Hodisch

. 2020 ; 21 (1) : 82. [pub] 20201125

Language English Country Great Britain

Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026408

BACKGROUND: To study the pharmacokinetic and -dynamic behavior of landiolol in the presence of dobutamine in healthy subjects of European ancestry. METHODS: We conducted a single-center, prospective randomized study in 16 healthy subjects each receiving an infusion of dobutamine sufficient to increase heart rate by 30 bpm followed by a 60 min infusion of 10 μg/kg/min landiolol. RESULTS: Dobutamine-induced increases in heart rate were stable for at least 20 min before a 60 min landiolol- infusion was started. The dobutamine effects were rapidly antagonized by landiolol within 16 min. A further slight decrease in heart rate during 20-60 min of the landiolol infusion occurred as well. Upon termination of landiolol infusion, heart rate and blood pressure recovered rapidly in response to the persisting dobutamine infusion but did not return to the maximum values before landiolol infusion. The pharmacokinetic parameters of landiolol in presence of dobutamine showed a short half-life (3.5 min) and a low distribution volume (0.3 l/kg). No serious adverse events were observed. CONCLUSION: Landiolol can antagonize the dobutamine-induced increases in heart rate and blood pressure in a fast way. A rapid bradycardic effect until steady-state plasma levels is followed by a slow heart rate reduction. The latter can be attributed to an early desensitization to dobutamine. Consequently, after termination of landiolol, the heart rate did not achieve maximum pre-landiolol values. The pharmacokinetics of landiolol during dobutamine infusion are similar when compared to short- and long-term data in Caucasian subjects. Landiolol in the given dose can thus serve as an antagonist of dobutamine-induced cardiac effects. TRIAL REGISTRATION: Registration number 2010-023311-34 at the EU Clinical Trials Register, registration date 2010-12-21.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026408
003      
CZ-PrNML
005      
20211026132927.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s40360-020-00462-x $2 doi
035    __
$a (PubMed)33239108
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Krumpl, Günther $u MRN Medical Research Network GmbH, Postgasse 11/22, A-1010, Vienna, Austria. g.krumpl@medresnet.com
245    10
$a Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults / $c G. Krumpl, I. Ulč, M. Trebs, P. Kadlecová, J. Hodisch
520    9_
$a BACKGROUND: To study the pharmacokinetic and -dynamic behavior of landiolol in the presence of dobutamine in healthy subjects of European ancestry. METHODS: We conducted a single-center, prospective randomized study in 16 healthy subjects each receiving an infusion of dobutamine sufficient to increase heart rate by 30 bpm followed by a 60 min infusion of 10 μg/kg/min landiolol. RESULTS: Dobutamine-induced increases in heart rate were stable for at least 20 min before a 60 min landiolol- infusion was started. The dobutamine effects were rapidly antagonized by landiolol within 16 min. A further slight decrease in heart rate during 20-60 min of the landiolol infusion occurred as well. Upon termination of landiolol infusion, heart rate and blood pressure recovered rapidly in response to the persisting dobutamine infusion but did not return to the maximum values before landiolol infusion. The pharmacokinetic parameters of landiolol in presence of dobutamine showed a short half-life (3.5 min) and a low distribution volume (0.3 l/kg). No serious adverse events were observed. CONCLUSION: Landiolol can antagonize the dobutamine-induced increases in heart rate and blood pressure in a fast way. A rapid bradycardic effect until steady-state plasma levels is followed by a slow heart rate reduction. The latter can be attributed to an early desensitization to dobutamine. Consequently, after termination of landiolol, the heart rate did not achieve maximum pre-landiolol values. The pharmacokinetics of landiolol during dobutamine infusion are similar when compared to short- and long-term data in Caucasian subjects. Landiolol in the given dose can thus serve as an antagonist of dobutamine-induced cardiac effects. TRIAL REGISTRATION: Registration number 2010-023311-34 at the EU Clinical Trials Register, registration date 2010-12-21.
650    _2
$a beta blokátory $x aplikace a dávkování $x farmakokinetika $7 D000319
650    _2
$a dospělí $7 D000328
650    _2
$a krevní tlak $x účinky léků $x fyziologie $7 D001794
650    _2
$a kardiotonika $x aplikace a dávkování $x farmakokinetika $7 D002316
650    _2
$a klinické křížové studie $7 D018592
650    _2
$a dobutamin $x aplikace a dávkování $x farmakokinetika $7 D004280
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a srdeční frekvence $x účinky léků $x fyziologie $7 D006339
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a morfoliny $x aplikace a dávkování $x farmakokinetika $7 D009025
650    _2
$a prospektivní studie $7 D011446
650    _2
$a močovina $x aplikace a dávkování $x analogy a deriváty $x farmakokinetika $7 D014508
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ulč, Ivan $u Center for Pharmacology and Analysis (CEPHA) s.r.o, Plzeň, Czech Republic
700    1_
$a Trebs, Michaela $u AOP Orphan Pharmaceuticals AG, Vienna, Austria
700    1_
$a Kadlecová, Pavla $u Aixial s.r.o., Brno, Czech Republic
700    1_
$a Hodisch, Juri $u AOP Orphan Pharmaceuticals AG, Vienna, Austria
773    0_
$w MED00195156 $t BMC pharmacology & toxicology $x 2050-6511 $g Roč. 21, č. 1 (2020), s. 82
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33239108 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132934 $b ABA008
999    __
$a ok $b bmc $g 1715200 $s 1146915
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 1 $d 82 $e 20201125 $i 2050-6511 $m BMC pharmacology & toxicology $n BMC Pharmacol Toxicol $x MED00195156
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options